IL141663A - Altriptan Hydrobromide Monohydrate, its preparation and pharmaceutical preparations containing it - Google Patents

Altriptan Hydrobromide Monohydrate, its preparation and pharmaceutical preparations containing it

Info

Publication number
IL141663A
IL141663A IL14166399A IL14166399A IL141663A IL 141663 A IL141663 A IL 141663A IL 14166399 A IL14166399 A IL 14166399A IL 14166399 A IL14166399 A IL 14166399A IL 141663 A IL141663 A IL 141663A
Authority
IL
Israel
Prior art keywords
eletriptan hydrobromide
monohydrate
eletriptan
hydrobromide monohydrate
water
Prior art date
Application number
IL14166399A
Other languages
English (en)
Hebrew (he)
Other versions
IL141663A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL141663A0 publication Critical patent/IL141663A0/xx
Publication of IL141663A publication Critical patent/IL141663A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
IL14166399A 1998-11-27 1999-11-01 Altriptan Hydrobromide Monohydrate, its preparation and pharmaceutical preparations containing it IL141663A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9825988.0A GB9825988D0 (en) 1998-11-27 1998-11-27 Indole derivatives
PCT/IB1999/001754 WO2000032589A1 (en) 1998-11-27 1999-11-01 Eletriptan hydrobromide monohydrate

Publications (2)

Publication Number Publication Date
IL141663A0 IL141663A0 (en) 2002-03-10
IL141663A true IL141663A (en) 2004-05-12

Family

ID=10843140

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14166399A IL141663A (en) 1998-11-27 1999-11-01 Altriptan Hydrobromide Monohydrate, its preparation and pharmaceutical preparations containing it

Country Status (53)

Country Link
US (2) US20020013358A1 (hu)
EP (1) EP1135381B1 (hu)
JP (1) JP3777094B2 (hu)
KR (1) KR100413739B1 (hu)
CN (1) CN1131860C (hu)
AP (1) AP2001002149A0 (hu)
AR (1) AR024232A1 (hu)
AT (1) ATE273300T1 (hu)
AU (1) AU754731B2 (hu)
BG (1) BG64706B1 (hu)
BR (1) BR9915692A (hu)
CA (1) CA2352392C (hu)
CO (1) CO5150178A1 (hu)
CR (1) CR6325A (hu)
CU (1) CU23269A3 (hu)
CZ (1) CZ295472B6 (hu)
DE (1) DE69919388T2 (hu)
DK (1) DK1135381T3 (hu)
DZ (1) DZ2948A1 (hu)
EA (1) EA003551B1 (hu)
EE (1) EE04914B1 (hu)
ES (1) ES2224701T3 (hu)
GB (1) GB9825988D0 (hu)
GC (1) GC0000113A (hu)
GE (1) GEP20043183B (hu)
GT (1) GT199900202A (hu)
HK (1) HK1042898B (hu)
HN (1) HN1999000196A (hu)
HR (1) HRP20010398B1 (hu)
HU (1) HUP0105308A3 (hu)
ID (1) ID28802A (hu)
IL (1) IL141663A (hu)
IS (1) IS2238B (hu)
MA (1) MA26708A1 (hu)
MY (1) MY124078A (hu)
NO (1) NO320798B1 (hu)
NZ (1) NZ510055A (hu)
OA (1) OA11671A (hu)
PA (1) PA8485701A1 (hu)
PE (1) PE20001299A1 (hu)
PL (1) PL194503B1 (hu)
PT (1) PT1135381E (hu)
RS (1) RS50002B (hu)
SI (1) SI1135381T1 (hu)
SK (1) SK285774B6 (hu)
SV (1) SV1999000204A (hu)
TN (1) TNSN99221A1 (hu)
TR (1) TR200101493T2 (hu)
TW (1) TWI246512B (hu)
UA (1) UA68402C2 (hu)
UY (2) UY25823A1 (hu)
WO (1) WO2000032589A1 (hu)
ZA (1) ZA200102681B (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0018968D0 (en) * 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
MXPA05010070A (es) 2003-04-11 2005-11-23 Pfizer Combinacion farmaceutica.
US6927296B2 (en) 2003-07-23 2005-08-09 Pfizer Inc. Process
GB0317229D0 (en) * 2003-07-23 2003-08-27 Pfizer Ltd Improved process
EP2093224A1 (en) 2007-05-01 2009-08-26 Plus Chemicals B.V. Process for preparing eletriptan hydrobromide form beta
US20080319205A1 (en) * 2007-05-29 2008-12-25 Roman Bednar Process for preparing 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole
US20100285075A1 (en) * 2007-12-17 2010-11-11 Actavis Group Ptc Ehf Novel Hemioxalate Salt of Eletriptan
US20120027816A1 (en) * 2009-02-25 2012-02-02 Actavis Group Ptc Ehf Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity
WO2010116386A2 (en) * 2009-04-08 2010-10-14 Biophore India Pharmaceuticals Pvt. Ltd. Novel polymorph of eletriptan hydrobromide and process for the preparation thereof
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
CN103893112A (zh) * 2012-12-31 2014-07-02 重庆圣华曦药业股份有限公司 氢溴酸依来曲普坦注射液
CN107954947A (zh) * 2016-10-14 2018-04-24 北京莱瑞森医药科技有限公司 沃替西汀氢溴酸盐晶型c及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952741A (en) * 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
US5474784A (en) * 1990-03-02 1995-12-12 British Technology Group Limited Dispensing device
DE10299004I2 (de) 1990-10-15 2006-03-16 Pfizer Indolderivate
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) * 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
EA002174B1 (ru) 1997-07-03 2002-02-28 Пфайзер Инк. Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин

Also Published As

Publication number Publication date
AU754731B2 (en) 2002-11-21
GB9825988D0 (en) 1999-01-20
TNSN99221A1 (fr) 2005-11-10
IS2238B (is) 2007-05-15
AP2001002149A0 (en) 2001-06-30
DK1135381T3 (da) 2004-11-15
JP2002531449A (ja) 2002-09-24
CN1328554A (zh) 2001-12-26
SI1135381T1 (en) 2004-10-31
HN1999000196A (es) 2005-11-26
ID28802A (id) 2001-07-05
HRP20010398B1 (en) 2004-12-31
YU18801A (sh) 2003-07-07
PE20001299A1 (es) 2000-12-01
BG105539A (en) 2001-12-29
NO20012584D0 (no) 2001-05-25
WO2000032589A1 (en) 2000-06-08
CZ295472B6 (cs) 2005-08-17
ATE273300T1 (de) 2004-08-15
EA003551B1 (ru) 2003-06-26
GEP20043183B (en) 2004-02-25
SK285774B6 (sk) 2007-08-02
HRP20010398A2 (en) 2002-06-30
NO20012584L (no) 2001-07-27
EE04914B1 (et) 2007-10-15
US7238723B2 (en) 2007-07-03
CO5150178A1 (es) 2002-04-29
DE69919388T2 (de) 2005-09-29
ES2224701T3 (es) 2005-03-01
EA200100297A1 (ru) 2001-08-27
PL347928A1 (en) 2002-04-22
CU23269A3 (es) 2008-04-09
NZ510055A (en) 2004-11-26
UY25823A1 (es) 2001-08-27
IS5868A (is) 2001-02-27
GT199900202A (es) 2001-05-19
CZ20011839A3 (cs) 2001-10-17
KR20010080594A (ko) 2001-08-22
HUP0105308A3 (en) 2003-01-28
RS50002B (sr) 2008-09-29
DE69919388D1 (de) 2004-09-16
SK6992001A3 (en) 2002-01-07
AR024232A1 (es) 2002-09-25
HUP0105308A2 (hu) 2002-05-29
CA2352392C (en) 2006-01-24
KR100413739B1 (ko) 2004-01-03
SV1999000204A (es) 2000-10-16
UA68402C2 (en) 2004-08-16
PL194503B1 (pl) 2007-06-29
US20020013358A1 (en) 2002-01-31
UY25825A1 (es) 2000-08-21
TR200101493T2 (tr) 2002-02-21
IL141663A0 (en) 2002-03-10
MY124078A (en) 2006-06-30
DZ2948A1 (fr) 2004-03-15
AU6225399A (en) 2000-06-19
BG64706B1 (bg) 2005-12-30
EP1135381B1 (en) 2004-08-11
GC0000113A (en) 2005-06-29
PA8485701A1 (es) 2000-09-29
TWI246512B (en) 2006-01-01
CN1131860C (zh) 2003-12-24
EE200100285A (et) 2002-08-15
MA26708A1 (fr) 2004-12-20
CA2352392A1 (en) 2000-06-08
EP1135381A1 (en) 2001-09-26
JP3777094B2 (ja) 2006-05-24
HK1042898A1 (en) 2002-08-30
ZA200102681B (en) 2002-07-02
HK1042898B (zh) 2004-10-08
PT1135381E (pt) 2004-10-29
NO320798B1 (no) 2006-01-30
US20050131237A1 (en) 2005-06-16
OA11671A (en) 2005-01-12
CR6325A (hu) 2008-07-02
BR9915692A (pt) 2001-08-14

Similar Documents

Publication Publication Date Title
AU754731B2 (en) Eletriptan hydrobromide monohydrate
AU779580B2 (en) Polymorphic salt of an anti-migraine drug
MXPA01005313A (en) Eletriptan hydrobromide monohydrate

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees